Advertisement
Annovis Bio Says FDA Authorizes Phase 2/3 Trial For Buntanetap In Alzheimer's Disease
(RTTNews) - Annovis Bio, Inc. (ANVS), a late-stage clinical drug platform company, announced Thursday that the U.S. Food and Drug Administration (FDA) has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease (AD).
Following the submission of the Phase 2a clinical safety data and the chronic toxicology data in animals, the Company requested approval to further pursue the development of buntanetap in AD.
The FDA approved the Company's development plan, study protocol and authorized the initiation of the Phase 2/3 clinical study of buntanetap in AD.
For More Such Health News, visit rttnews.com
read more
Annovis Bio Says Phase III Study Data Release For Buntanetap In Parkinson's Disease Postponed
Drug platform company Annovis Bio, Inc. (ANVS) announced Wednesday a postponement in the Phase III study data release for buntanetap in Parkinson's Disease. This adjustment is due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results.
RTTNews
|
485 dagar sedan
U.S. New Home Sales Spike From Downwardly Revised Level In April
The Commerce Department released a report on Friday showing new home sales in the U.S. in the month of April spiked compared to a significantly downwardly revised level in March. The report said new home sales soared by 10.9 percent to an annual rate of 743,000 in April after jumping by 2.6 percent to a downwardly revised rate of 670,000 in March.
RTTNews
|
1h 27minuter sedan
Germany Logs Stronger Growth On Tariff Threats
The German economy grew at a stronger-than-estimated pace in the first quarter as higher tariff threats by the U.S. administration led to the frontloading of orders for the country's goods, lifting exports and industrial production. Gross domestic product grew 0.4 percent, which was double the initial estimate of 0.2 percent, a detailed report from Destatis revealed on Friday.
RTTNews
|
2h 33minuter sedan
Bay Street Likely To Open On Negative Note On Tariff Concerns
Canadian shares look headed for a weak start Friday morning as tariff concerns resurfaced after U.S. President Donald Trump threatened 50% tariffs on EU goods from June 1. Weak oil prices could hurt energy stocks and add to market's downside.
RTTNews
|
3h 40minuter sedan
FTSE Pares Early Gains, Up Marginally In Cautious Trade
U.K. stocks moved higher Friday morning, reacting to data showing a notable rise in retail sales, and survey showing strong consumer confidence. However, stocks pared gains subsequently in cautious trade and the market was up just marginally a little past noon.
RTTNews
|
4h 42minuter sedan
Pound Rises On Robust U.K. Retail Sales Data
The British pound strengthened against other major currencies in the European session on Friday, after U.K. retail sales rebounded more than expected in April as good weather boosted food store sales.
RTTNews
|
4h 57minuter sedan
CAC 40 Slips On Weak Consumer Confidence Data
French stocks are drifting lower on Friday, giving up early gains amid cautious moves by investors due to persisting concerns about U.S. fiscal outlook, and continued uncertainty surrounding Trump administration's tariff moves. Data showing a drop in French consumer confidence also weigh on sentiment.
RTTNews
|
5h 14minuter sedan
Pound Rises Against Majors
The British pound strengthened against other major currencies in the European session on Friday.
RTTNews
|
5h 23minuter sedan
